Solventum Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bryan C. Hanson
- Full Time Employees
- 20,000
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 1750 Yankee Doodle Road Maplewood MN United States 55121
- IPO Date
- Apr 1, 2024
- CIK
- 0001964738
- Website
- solventum.com
- Similar Companies
- Business
- Solventum Corporation (NYSE: SOLV) develops, manufactures and commercializes healthcare solutions at the intersection of health, material and data science, including advanced wound care such as negative pressure wound therapy and surgical incision management; infection prevention and skin integrity products; dental and orthodontic bonding systems and consumables; revenue cycle management and health information systems software; and purification and filtration solutions for biopharmaceutical manufacturers. The company, spun off from 3M and became independently publicly traded on April 1, 2024, after incorporation in 2023 as a successor to 3M's health care business with over 70 years of history, maintains headquarters in St. Paul, Minnesota, and employs more than 20,000 people across approximately 38 countries with significant operations in the United States (over 50% of sales), EMEA, Asia-Pacific including China, and other international markets; it operates through three primary segments post recent divestiture, MedSurg (largest, encompassing advanced wound care, oral care and medical device components), Dental Solutions, and Health Information Systems, serving hospitals, clinics, dental professionals, biopharma firms and healthcare providers. Recent major changes include the February 2025 announcement and subsequent completion of the $4.1 billion sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. expected by end-2025 for net proceeds of about $3.4 billion primarily to reduce debt as part of its multi-phase transformation plan following independence; alongside scheduling an Investor Day in March 2025 to outline long-range strategy and a definitive agreement to acquire Acera Surgical to bolster surgical technologies and patient outcomes.
Company News
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Solventum (SOLV) Tops Q3 Earnings Estimates
Solventum Reports Third Quarter 2026 Financial Results
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics
SOLV Energy Expands High-Voltage Infrastructure Capabilities with Acquisition of ASB Energy Services
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Here's Why Solventum (SOLV) is a Strong Value Stock
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
SOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Stock Picks From Seeking Alpha's September 2026 New Analysts
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)